Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 21 September 2016 | By Zachary Brennan
The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) plans to leverage real-world evidence and more “Big Data” for regulatory decisions, according to a list of its science priorities for 2017.
As far as what will change between 2016 and 2017, the 13-page report says that thanks to more “needs submissions from staff,” CDRH was able to identify new topic areas, including clinical trial design and precision medicine, as well as describe existing topic areas in greater detail.
“Although the area of human factors is not prominently identified as a priority, it is still an unmet need and is reflected in the descriptions of other FY 2017 top ten priorities (e.g. infection control and predicting medical device clinical performance). Patient reported outcome measures and patient preference were combined as patient input and the reprocessing priority was renamed to the more inclusive topic of infection control,” the report says.
The top ten CDRH regulatory science priorities include:
Tags: CDRH, device priorities, real-world data for devices